Aviado · Research
Longevity Daily
Friday, October 16, 2026
Listen
Today's Brief
A Harvard-led study in Nature Aging identifies SRSF1 — an RNA splicing factor nobody had on their radar — as a gene that cuts frailty by 44% and extends mouse lifespan by 14%, marking a genuinely fresh angle on cellular rejuvenation. In cognitive health, a large multicohort study links ADHD genetic predisposition to late-life cognitive impairment, while Tiziana Life Sciences completes enrollment in a Phase 2 trial of intranasal foralumab, one of the most mechanistically novel Alzheimer's therapies currently in testing. A 24-week human RCT confirms metformin lengthens telomeres in prediabetes, Aviado delivers a clear breakdown of B-complex vitamins and homocysteine evidence, and the NYT asks whether longevity medicine has finally crossed into the mainstream.
10 stories5 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
Scientists Identify a Brain Molecule That Preserves Memory as We Age
Researchers publishing in Nature Neuroscience have identified an aging-sensitive secreted phospholipase that confers neuroprotection and cognitive resilience, a molecule that declines with age and leaves neurons increasingly vulnerable to damage and memory loss. The study shows the enzyme acts on two levels: supporting regeneration of damaged nerve projections and dampening harmful inflammatory signaling in surrounding brain cells. If this protective molecule can be maintained or restored, it could represent a compelling new drug target for preserving cognition in older adults.
Read more →ADHD Genetic Risk Is Tied to Greater Cognitive Decline in Later Life
A prospective multicohort study in Alzheimer's and Dementia finds that individuals with higher polygenic risk scores for ADHD face significantly greater incidence of cognitive impairment in older age, an association not observed for genetic risk from depression, bipolar disorder, or schizophrenia. The researchers note this applies to genetic predisposition rather than clinical diagnosis, suggesting shared neurobiological mechanisms may underlie both conditions. If you have ADHD or a family history, this adds another reason to prioritize brain-protective habits early and discuss cognitive monitoring with your doctor.
Read more →Tiziana Completes Enrollment in Phase 2 Trial of Intranasal Alzheimer's Drug
Tiziana Life Sciences has dosed the final patient in its Phase 2 trial of intranasal foralumab for mild Alzheimer's disease, completing enrollment for one of the most mechanistically novel Alzheimer's trials underway. Unlike the amyloid-clearing therapies dominating headlines, foralumab is an anti-CD3 monoclonal antibody delivered nasally, designed to modulate the brain's inflammatory immune response rather than target plaques. Results are expected to be among the most closely watched cognitive data readouts of 2027.
Read more →Supplements & Compounds
Metformin Lengthens Telomeres and Activates Longevity Genes in Human RCT
A 24-week randomized controlled trial in Asian Indian adults with prediabetes found that metformin therapy significantly increased leukocyte telomere length, telomerase activity, and longevity gene expression compared to controls, providing some of the most direct human evidence that metformin acts on biological aging markers and not just blood glucose. The study is small and conducted in a specific population, so broad generalizability requires caution, but the controlled design and specific mechanistic readouts make it one of the more credible metformin-as-geroprotective data points to date. If you are on the fence about metformin, this is the kind of study worth discussing with your physician.
Read more →Why NAD+ Supplements Don't Always Work — And What the Science Says to Do About It
A review published in Biology maps why SIRT1, the deacetylase enzyme that NAD+ precursors like NMN and NR are meant to activate, loses functional reserve with age and why that depletion may sit upstream of multiple age-related disorders at the cellular level. Critically, the analysis explains what human evidence actually supports: dose, form, and baseline NAD+ status all determine whether supplementing translates into meaningful SIRT1 activation. If you take NMN or NR and wonder why results vary so much between individuals, this is the mechanistic context that makes sense of it.
Read more →B-Complex Vitamins and Homocysteine: What 26,000 Participants Actually Show
Meta-analyses covering more than 26,000 participants confirm that standard B-complex supplementation at doses of B6 2 mg or more, folate 400 to 800 mcg, and B12 6 mcg or more daily reliably lowers circulating homocysteine by 2 to 4 micromoles per liter, one of the most reproducible biomarker effects in supplement research. Aviado's analysis is candid about the limits: while the biochemical mechanism is airtight because B vitamins are essential cofactors in the one-carbon methylation cycle that clears homocysteine, consistent reductions in cardiovascular events or cognitive outcomes have not followed consistently in trials. If you track homocysteine, a standard B-complex is among the most evidence-supported tools available, just without guarantees of downstream clinical benefit.
Read the full Aviado analysis →Research & Papers
Harvard Scientists Reverse Aging With a Single Gene — And It Is Not a Yamanaka Factor
Harvard-led researchers built a machine-learning gene expression clock from aged human fibroblasts, then screened thousands of candidate factors to find what could reprogram those cells toward a younger state, landing on SRSF1, an RNA splicing regulator that had never appeared on the aging field's radar. In aged mice, inducible SRSF1 overexpression cut frailty progression by 44 percent and extended median lifespan by 14 percent in groups of 9 to 10 animals, without erasing cellular identity the way the riskier Yamanaka factor approach does. The mechanism, restoring RNA splicing fidelity that frays with age, is conserved across species, which is why researchers are calling SRSF1 a genuinely promising geroprotective target. This is still mouse data with small group sizes, but the Nature Aging publication and mechanistic clarity make it one of the most credible aging-reversal findings in recent memory.
Read more →What a Biological Age Test Can Actually Tell You — And What It Cannot
The New York Times delivers a clear-eyed explainer on biological age testing, tracing the science from Steve Horvath's landmark 2013 DNA methylation clock through today's proliferating consumer products. The piece is a necessary corrective at a moment when biological age scores are everywhere: these tools measure epigenetic modification patterns that correlate with age, but the gap between a promising research assay and a clinically validated diagnostic remains substantial. Worth forwarding to anyone who has just received their first biological age score and is wondering what to actually do about it.
Read more →Lifestyle & Nutrition
Your Gut Microbiome May Be Why Exercise Protects Aging Muscles
Fight Aging! synthesizes emerging research on how the gut microbiome and physical exercise together shape muscle aging and the path to frailty, with evidence that both factors act on overlapping inflammatory pathways. In animal models, microbiome rejuvenation via fecal transplants from young donors has improved health markers in aged recipients, raising the question of whether exercise partly works by maintaining a younger gut microbial community. The human translation is still early-stage, but it adds another mechanistic layer to why regular physical activity seems to protect muscle tissue in ways that go well beyond simple load-bearing.
Read more →Industry & Policy
Is Longevity Medicine Going Mainstream? The NYT Investigates
The New York Times examines whether longevity medicine, from biomarker panels and preventive diagnostics to personalized testing at clinics like Fountain Life, is crossing from niche experiment to mainstream healthcare. The piece includes candid quotes from Fountain Life's chief medical officer, who defends therapies backed by early promising data while drawing a deliberate line between experimental interventions and standard of care. For anyone considering a longevity clinic, this is a useful calibration: the sector is growing rapidly and attracting genuine credibility, but the evidence base is still catching up to the enthusiasm.
Read more →